Abbott expects a ‘few hundred million' in tariff costs in 2025 [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
By the numbers Q1 revenue: $10.36 billion 4% increase year over year Medical device sales: $4.9 billion 9.9% increase year over year Net earnings: $1.33 billion 8.2% increase year over year Abbott expects a “few hundred million dollars” of impact from tariffs this year, CEO Robert Ford told investors on a Wednesday earnings call. Ford sought to assure investors that the company has strategies to mitigate the damage from President Donald Trump's tariff strategy. “Everything is pretty certain for us in terms of how we're executing and the expectations we have for products,” Ford said. Abbott is maintaining its forecast for adjusted diluted earnings per share in 2025. Prior to the tariffs, the CEO added, Abbott considered raising its earnings forecast for 2025 because of the momentum the company saw in its base business. The approach dovetails with healthcare giant Johnson & Johnson's tariff assessment. J&J kept its earnings forecast Tuesday despite calling out a tar
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care* [Yahoo! Finance]Yahoo! Finance
- U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*PR Newswire
- These Institutional Investors Are Raising Their Stakes in Johnson & Johnson Stock. Should You Do the Same? [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson (NYSE:JNJ) was given a new $197.00 price target on by analysts at Morgan Stanley.MarketBeat
- Is J&J's 45.8% 2025 Surge Justified by Its Cash Flow and Earnings Outlook? [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 10/14/25 - Beat
JNJ
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- JNJ's page on the SEC website